Introduction
============

Influenza viruses, which are enveloped, single-stranded negative-sense RNA viruses, belong to the *Orthomyxoviridae* family and cause respiratory diseases in humans around the world. While there are four types of seasonal influenza viruses -- types A, B, C, and *Thogotovirus* -- influenza A and B viruses in particular can cause seasonal epidemics that have high rates of morbidity and mortality ([@B25]). The genomes of influenza A and B viruses are composed of the following eight RNA segments: segment 1, RNA polymerase PB2 unit; segment 2, RNA polymerase PB1 unit; segment 3, RNA polymerase PA unit; segment 4, hemagglutinin (HA); segment 5, nucleoprotein (NP); segment 6, neuraminidase (NA); segment 7, matrix (M); and segment 8, non-structural protein (NS).

The genomes of influenza viruses frequently develop genetic changes and have a high level of genetic diversity, which contributes to their ability to evade the human immune system ([@B7]). To cope with the emergence of new influenza virus strains and select appropriate vaccine strains, considerable effort is being devoted to monitoring the genetic rearrangements of these viruses ([@B6]; [@B24]). A simple amplification method using RT-PCR for influenza virus has been developed and is contributing to the efficient surveillance of influenza viruses via next-generation sequencing (NGS) ([@B31]; [@B32]; [@B30]). NGS technology is used in a wide range of applications, including population surveillance for emerging strains and the subsequent creation of new vaccines, outbreak research in communities, and tracking of nosocomial infections ([@B2]; [@B9]; [@B11]; [@B14]). However, amplicon sequencing using NGS platforms such as 454 (Roche Life Science, Penzberg, Germany), the Illumina platform (Illumina, San Diego, CA, United States), and Ion Torrent technology (Thermo Fisher Scientific, Waltham, MA, United States) has high initial and running costs and is time-consuming. Therefore, it is challenging to establish facilities with an NGS platform for the surveillance of influenza viruses in developing countries ([@B26]).

The MinION nanopore sequencer, recently developed by Oxford Nanopore Technologies (ONT; Oxford, United Kingdom), is a palm-size portable sequencer that can read long-read single DNA molecules in real time and is regarded as third-generation DNA sequencing technology. The most notable feature of the MinION sequencer is its portability, which makes it different from other NGS platforms. For this reason, the MinION sequencer has been used as an alternative means of whole genome sequencing (WGS) and can be used for genomic surveillance and infection control for certain pathogens, taking advantage of its high portability, and its quick and easy sample preparation. However, its high sequence error rate remains a challenge ([@B19], [@B21]; [@B10]). In 2017, ONT released the new 1D^2^ method, which has higher single-read accuracy than the standard 1D method^[1](#fn01){ref-type="fn"}^. The WGS method for influenza A virus using the MinION sequencer has been previously reported ([@B27]). However, the method still has some practical problems, such as a high per-sample cost because of the single plex sequencing, applicability to only influenza A virus, and unknown performance in clinical settings.

In this study, we developed, a quick and accurate multiplex WGS method for influenza A and B viruses using clinical specimens, the MinION nanopore sequencer, and the 1D^2^ method.

Materials and Methods {#s1}
=====================

Clinical Samples and Ethics
---------------------------

Clinical samples were collected from suspected influenza patients at the Japan Self-Defense Forces Central Hospital and Medical Office of Camp Asaka, Tokyo, Japan, from December 2017 to April 2018. All patients were diagnosed based on commercially available rapid diagnostic tests for influenza using nasopharyngeal swab specimens, according to the manufacturer's instructions (QuickNavi-Flu 2; Denka Seiken, Niigata, Japan). In particular, the samples obtained were composed of two specimens, which were separated for subsequent tests. One swab was used for the rapid diagnosis of influenza and the other for the subsequent RNA extraction of influenza virus. Each swab specimen was stored at -80°C until just before use. A diagnosis of influenza was ultimately confirmed via RT-PCR according to previously reported protocols for influenza viruses A (M30F2/08 and M264R3/08 for all subtypes) and B (Bvf224 and Bvr507 for Victoria lineage, and Bvf226 and BYr613 for Yamagata lineage). Both primer sets are recommended for the detection of influenza viruses by the World Health Organization \[[@B29]\]. To evaluate our procedures in clinical practice, 13 nasopharyngeal swab samples were confirmed as influenza-positive (6 = influenza A virus and 7 = influenza B virus Yamagata lineage) and used in our study.

This study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Ethics Committee of the Self-Defense Forces Central Hospital (No. 29-012). All samples were collected after written informed consent was obtained.

RNA Extraction and DNase Treatment
----------------------------------

Total RNA was extracted using a High Pure Viral RNA Kit (Roche Life Science) according to the manufacturer's instructions. Additionally, each eluted RNA was treated with 4U of TURBO DNase (Thermo Fisher Scientific) for 30 min at 37°C to remove the human genomic DNA and purified again by Agencourt RNAClean XP (Beckman Coulter, Brea, CA, United States) according to the manufacturer's instructions.

Multiplex RT- PCR and Purification
----------------------------------

Supernatants of each purified RNA sample (5 μL) were then used for multiplex RT-PCR reactions. In this scheme, viral RNA segments of influenza A (PB2 = 2.3 kb, PB1 = 2.3 kb, PA = 2.2 kb, HA = 1.8 kb, NP = 1.6 kb, NA = 1.4 kb, M = 1.0 kb, and NS = 0.9 kb) were simultaneously amplified using two primers (Uni12, Uni13; Supplementary Table [S1](#SM1){ref-type="supplementary-material"}) targeting the highly conserved sequence of viral RNA termini, which are commonly present at the ends of the PB2, PB1, PA, HA, NP, NA, M, and NS genome segments, following protocols previously reported for influenza A virus ([@B31]). For influenza B (PB2 = 2.3 kb, PB1 = 2.3 kb, PA = 2.3 kb, HA = 1.8 kb, NP = 1.8 kb, NA = 1.5 kb, M = 1.1 kb, and NS = 1.0 kb), multiplex amplification was simultaneously performed with multiple primer sets targeting the corresponding conserved sequence of each viral RNA termini in accordance with a previous report (Supplementary Table [S1](#SM1){ref-type="supplementary-material"}; [@B32]). Multiplex RT-PCR amplicons were generated by the SuperScript^TM^ III One-Step RT-PCR System with Platinum^TM^ Taq High Fidelity DNA Polymerase (Thermo Fisher Scientific). PCR products were analyzed using the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, United States) with an Agilent DNA 7500 Kit (Agilent Technologies). Each PCR product was purified again using Agencourt AMPure XP according to the manufacturer's instructions.

Sequencing of Multiplex RT-PCR Products Using the Illumina MiSeq Sequencer
--------------------------------------------------------------------------

The complete influenza virus genome was analyzed with multiplex RT-PCR amplicon sequencing using the Illumina MiSeq platform. Paired-end libraries for MiSeq platform were prepared using Nextera XT DNA Library Prep Kit (Illumina) and Nextera XT Index Kit (Illumina), and sequencing was performed using a 300-cycle (2 × 150-bp paired-end) MiSeq v2 reagent kit (Illumina) via MiSeq platform according to the manufacturer's protocols.

Analysis of Illumina MiSeq Platform Data
----------------------------------------

Low-quality reads in demultiplexed data were removed and 3′ terminal nucleotides were trimmed with SeqKit and mapped with BWA-MEM (v 0.7.15) using the reference sequences for influenza A (GenBank; CY259943-50) and influenza B viruses (GenBank; MH233733-40). Single nucleotide variant calling from mapped data was obtained by Samtools, Picard, and GATK via "HaplotypeCaller" commands ([@B4]).

Sequencing of PCR Products Using the MinION Sequencer
-----------------------------------------------------

To enable use of multiplex MinION sequencing at reduced cost with shorter analysis times, each specific barcode tag for the MinION was added at the start of each reverse primer for eight viral RNA segments (influenza A, Uni13/Inf1-Bc; influenza B, UniR-Bc) (Supplementary Table [S1](#SM1){ref-type="supplementary-material"}). An additional nested PCR assay with custom barcoded primers was performed consecutively to match the sequence reads to the correct clinical specimens. Briefly, 1 μL of 10 ng from each purified PCR amplicon of eight viral RNA segments was used as template DNA. The nested PCR assays were performed using KAPA HiFi HotStart ReadyMix PCR Kit (Kapa Biosystems, Wilmington, MA, United States) and thermal cycling was carried out under the following conditions: 94°C for 5 min, followed by 18 cycles at 98°C for 10 s, 60°C for 30 s, 72°C for 120 s, and a final extension at 72°C for 5 min. The nested PCR products with each ONT-specific barcode tag were analyzed using the Agilent 2100 Bioanalyzer with an Agilent DNA 7500 Kit. Each PCR product was consequently re-purified with Agencourt AMPure XP according to the manufacturer's instructions. The nested PCR amplicons (300 ng each) were measured by Qubit 3.0 Fluorometer (Thermo Fisher Scientific) and simultaneously processed for library preparation using the SQK-LSK308 1D^2^ Sequencing Kit (ONT) according to the manufacturer's instructions. After the MinION Platform QC run, the mixed DNA library derived from 13 clinical samples was loaded into a single MinION Flow Cell (FLO-MIN107 R9.5 Version) and the "NC_48Hr_sequencing_FLO-MIN107_SQK-LSK308_plus_basecaller" protocol was initiated using MinKNOW software (v 1.4.1, ONT).

Analysis of MinION Data
-----------------------

Local basecalling was performed using MinKNOW automatically in real time. 1D^2^ reads were generated from FAST5 reads by Albacore (v 2.2.1). Low-quality reads and \< 500- and \> 3000-length reads were removed by SeqKit (v 0.8.1). Demultiplexing and adapter trimming was performed using Porechop (v 0.2.2), and all ONT-barcode data were eventually collected and mapped by Minimap2 (v 0.7.15) using the reference sequences for influenza A H3N2 (GenBank; CY259943-50) and influenza B Yamagata lineage (GenBank; MH233733-40). Single nucleotide variant calling from mapped data was obtained by Samtools and BCFtools (v 1.5.0) via the mpileup command, and variant calling under 10× read depth was filtered. Mapped data were visualized by IGV software (v 2.3.8) and analyzed by Samtools and Qualimap (v 2.2.1).

Results
=======

Multiplex RT-PCR for Clinical Samples
-------------------------------------

All eight segments of influenza gene from each nasopharyngeal swab samples were successfully amplified with multiplex RT-PCR. Based on the results of RT-PCR amplicon sequencing using the Illumina MiSeq, 6 samples were identified as influenza A H3N2 subtype and 7 samples were identified as influenza B Yamagata lineage. The complete influenza virus genomes were deposited in the Global Initiative on Sharing All Influenza Data database (GISAID: EPI_ISL_313902 - 313914).

Results of MinION Sequencing, Mapped for Reference Genomes
----------------------------------------------------------

Amplicons with ONT-specific barcodes were successfully amplified by nested RT-PCR. Finally, a total of 2,120,657 1D reads (total 3.2 Gbases) were generated within 48 h after the start of MinION sequencing, and a total of 71,066 1D^2^ reads (total 101 Mbases) were generated by Albacore. Among the total collected reads, 1.87% ± 1.42% and 5.97% ± 2.83% were classified into ONT-barcodes after barcode demultiplexing as 1D and 1D^2^, respectively. Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}, and Supplementary Table [S2](#SM1){ref-type="supplementary-material"} show the results of mapped data for reference sequences by Minimap2, and Figures [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"} show the depth of coverage for the reference sequences per sample. The mean coverage per sample for influenza A virus was 1,578 and 89 and that for influenza B virus was 6,545 and 86 for 1D and 1D^2^, respectively. The raw sequence data of the Illumina MiSeq and MinION sequencers were deposited in the Sequence Read Archive (SRA: PRJNA491222).

###### 

Results of whole genome sequencing of influenza A virus using the MinION sequencer.

  Influenza A virus (*n* = 6)                                                  
  ----------------------------- -------- ------- -------- ------------ ------- -------
  PB2                           2,316    1D      1,988    3,654,198    1,878   99.94
                                         1D^2^   115      205,455      98      99.98
  PB1                           2,316    1D      2,723    4,348,554    2,303   99.92
                                         1D^2^   146      226,946      113     99.94
  PA                            2,209    1D      3,056    5,087,913    4,226   99.94
                                         1D^2^   154      249,691      228     99,99
  HA                            1,737    1D      4,764    7,340,349    2,384   99.90
                                         1D^2^   271      395,417      127     99.99
  NP                            1,542    1D      2,716    3,676,187    2,861   99.93
                                         1D^2^   158      195,941      117     99.97
  NA                            1,441    1D      3,320    4,121,981    5,497   99.94
                                         1D^2^   144      168,456      303     99.97
  M                             1,002    1D      5,889    5,508,393    2,189   99.98
                                         1D^2^   362      303,262      111     100
  NS                            865      1D      5,137    4,081,978    2,816   100
                                         1D^2^   273      206,650      145     100
  Total                         13,428   1D      38,548   37,819,556   1,578   99.94
                                         1D^2^   3,568    1,951,821    89      99.98
                                                                               

###### 

Results of whole genome sequencing of influenza B virus by MinION sequencer.

  Influenza B virus (*n* = 7)                                                   
  ----------------------------- -------- ------- -------- ------------ -------- -------
  PB2                           2,367    1D      1,830    6,919,598    1,839    99.93
                                         1D^2^   96       2,957        133      99.98
  PB1                           2,340    1D      3,416    9,344,993    2,957    100
                                         1D^2^   182      4,108        203      100
  PA                            2,275    1D      3,974    16,632,486   4,108    99.95
                                         1D^2^   203      8,976        462      99,99
  HA                            1,853    1D      7,614    8,110,509    8,976    99.98
                                         1D^2^   416      4,466        248      99.99
  NP                            1,816    1D      4,172    11,079,003   4,466    99.97
                                         1D^2^   241      7,241        350      99.97
  NA                            1,530    1D      6,896    26,258,563   7,241    99.93
                                         1D^2^   377      22,735       1,472    99.97
  M                             1,155    1D      19,491   11,531,285   22,735   99.89
                                         1D^2^   1,364    10,858       628      100
  NS                            1,026    1D      8,533    94,229,268   10,858   99.96
                                         1D^2^   560      6,545        360      100
  Total                         14,362   1D      62,535   4,352,833    6,545    99.95
                                         1D^2^   4,973    1,839        86       99.98
                                                                                

![Coverage of MinION sequencing reads for a reference genome of influenza A virus. The upper graph shows the results of 1D reads and the lower graph shows results of 1D^2^ reads.](fmicb-09-02748-g001){#F1}

![Coverage of MinION sequencing reads for a reference genome of influenza B virus. The upper graph shows the results of 1D reads and the lower graph shows results of 1D^2^ reads.](fmicb-09-02748-g002){#F2}

Comparison With the Illumina MiSeq Platform
-------------------------------------------

Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}, and Supplementary Table [S3](#SM1){ref-type="supplementary-material"} show the nucleotide sequence identity between influenza gene segments sequenced using the MinION and Illumina MiSeq sequencers. The total accuracy rate of nucleotide sequence identity for influenza A virus when using the MinION sequencer was 99.94 and 99.98% and that for influenza B virus was 99.95 and 99.98% for 1D and 1D^2^, respectively. Variant calling from 1D^2^ rather than from 1D reads decreased the numbers of false positives and false negatives when using the MinION sequencer. The total recall and precision rates were 89.41% and 97.88% from 1D reads and 93.28 and 99.86% from 1D^2^ reads, respectively (Supplementary Table [S4](#SM1){ref-type="supplementary-material"}). The accuracy of the read level of MinION sequencing, which was calculated based on the mapped data for consensus influenza genome sequences generated from Illumina MiSeq reads, was 88.74% for 1D reads and 92.81% for 1D^2^ reads (Supplementary Table [S5](#SM1){ref-type="supplementary-material"}).

Discussion
==========

In this pilot study, we proposed a high-throughput MinION sequencing protocol that can be performed both in the field and in the clinical setting. We demonstrated that multiplex MinION sequencing could achieve variant calling easily and rapidly from 1D^2^ reads generated by combining multiplex RT-PCR methods for both influenza A and B viruses. In particular, sample processing and library preparation processes can be completed within 12 h without expensive or large experimental devices. Furthermore, the sequencing data can be analyzed in real time using a laptop computer. Moreover, samples can be prepared and sequenced without storage or transfer to a fully equipped laboratory. Therefore, our method would have the potential to allow real-time monitoring of both genetic rearrangements and the emergence of new influenza virus strains.

For accurate surveillance and vaccine subpopulation selection, a highly precise sequencing and variant calling method is always required. In particular, the recall and precision rate of the current MinION sequence technology were inferior to those of the Illumina MiSeq platform, and these limitations were similar to findings from other studies on genotyping using the MinION sequencer ([@B27]; [@B3]; [@B13]; [@B23]). Thus, our method is currently unsuitable to replace the Illumina platform. The high error rate and number of coverages of the MinION sequencer could affect the accuracy of variant calling because the read level accuracy rate was estimated to be about 88.74% for 1D and 92.81% for 1D^2^. In fact, false-positive results can be significantly reduced via high-quality 1D^2^ reads (precision rate: 97.88% from 1D reads vs. 99.86% from 1D^2^ reads). However, 1D^2^ reads would unfortunately still include false negatives due to single nucleotide polymorphisms (recall rate: 89.41% from 1D reads vs. 93.28% from 1D^2^ reads) because they would include deletion errors more frequently around the homopolymer sequence and have lower coverage than 1D reads. Further improvements in sequence accuracy of the MinION sequencer would make it possible to perform surveillance and vaccine subpopulation selection.

In this study, we used the clinically applicable amplicon sequencing protocol, to analyze influenza virus genome sequencing. Previously, [@B8] demonstrated that metagenomic sequencing analysis with the MinION sequencer could detect unknown emerging viruses without prior information and would be desirable for point-of-care genomic sequencing even in the developing world. However, its sequencing scheme still has lower sensitivity and specificity levels compared with the amplicon sequencing protocol of clinical samples, because of contamination from the large amount of host genome fragments in clinical samples ([@B22]; [@B20]). Moreover, there is currently no practical preparation kit for adding barcode tags in multiple-sample processing based on metagenomic sequencing with the 1D^2^ sequencing kit, even though multiplex sequencing is an essential technology that reduces the cost and time of analysis. Amplicon sequencing can solve one of these problems precisely by reducing contamination from host genome fragments via the added multiplex RT-PCR step. Furthermore, it is possible to simply add a barcode tag using nested PCR, thus enabling multiple sample processing. Of course, the DNA fragmentation step, including mechanical or chemical pretreatment, is required for the Illumina MiSeq platform because of its read length of up to 600 bp. However, a fragmentation step and additional device for amplicon sequencing are not necessary when using the MinION sequencer. This is because it can obtain long read data over 100 kb, which is another one of its advantageous characteristics ([@B12]). Unfortunately, even with high-fidelity DNA polymerase reactions, amplification by multiple RT-PCR and nested PCR could be a drawback as it may cause PCR-generated errors ([@B1]; [@B18]).

Multiplex sequencing with introduced barcode tag nucleotides would also contribute to improving the accuracy of pairing 1D sequence reads. In this study, we used nested PCR protocols to add 30-base ONT-specific barcodes against multiplex RT-PCR products of eight viral RNA segments and analyzed multiple samples simultaneously. In fact, in 1D^2^ sequencing using PCR amplicons, false-positive pairings between different samples could occur because 1D^2^ reads are generated with aberrant *in silico* chimeric reads from 1D reads. However, the addition of 30-base ONT-specific barcodes can effectively decrease the risk of false 1D^2^ pairing of strands.

Avian influenza types, such as influenza A virus subtypes H5N1 and H7N9, are likely to emerge with the potential to cause pandemics in developing countries ([@B17]; [@B5]). Furthermore, recent meta-analyses showed that morbidity and mortality are higher in patients with influenza viruses in developing countries than in those in developed countries ([@B15]; [@B16]). The WHO indicated an urgent need for strengthening local responses to emerging influenza viruses \[[@B28]\]. Whole genome analyses of influenza viruses using NGS is important for the surveillance of novel strains of influenza virus with genetic rearrangements and antiviral resistance. Compared with other NGS technologies, the MinION sequencer has excellent portability in addition to reduced initial installation costs, running costs, and analysis times. In the near future, the low-priced Flongle Flow Cell sequencing device^[2](#fn02){ref-type="fn"}^ -- an adapter for MinION flow cells that has 126 channels compared with 512 channels in the current MinION -- will become available and provide further versatility. Therefore, this novel procedure has the potential to be applicable as a surveillance technology for emerging influenza strains and for use even in situations where research facilities are inadequate.

Conclusion
==========

We developed novel high-throughput MinION sequencing methods for real-time sequencing of influenza A and B viruses using a portable sequencing setup with quick and easy sample preparation. Further improvement of read level accuracy and analytical tools is necessary to achieve better utilization of the MinION sequencer for both real-time monitoring of genetic rearrangements and evaluation of newly emerging viruses.
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